

April 6, 2020

Joshua Z. Schwartz, M.D., M.B.A.
Disease Area Head US Medical – Cardiovascular
Bristol-Myers Squibb Company
3401 Princeton Pike
Lawrence, NJ 08648
609-302-3293; joshua.schwartz2@bms.com

NCCN Guidelines® Panel: Cancer-Associated Venous Thromboembolic Disease Panel

Dear Panel Members,

On behalf of Bristol-Myers Squibb Company, I respectfully submit the enclosed clinical data for ELIQUIS® (apixaban) to the NCCN® Cancer-Associated Venous Thromboembolic Disease Panel for your consideration. This data was recently published in the *New England Journal of Medicine* on March 29, 2020. This study evaluated the use of apixaban for the treatment of venous thromboembolism associated with cancer.

FDA Approved Indications of ELIQUIS® (apixaban):

- To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.³
- For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.³
- For the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.³

Rationale: These data are being submitted in response to a standing request from NCCN® for new data.

As part of this submission, the following resources are included for your review.

1. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. [published online March 29, 2020] *N Engl J Med*. 2020. doi: 10.1056/NEJMoa1915103
2. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. [Supplementary Appendix] [published online March 29, 2020] *N Engl J Med*. 2020. doi: 10.1056/NEJMoa1915103
3. Product Information, ELIQUIS® (apixaban). Bristol-Myers Squibb Company, Princeton, NJ. March 2020

Thank you for your consideration.

Sincerely,

A handwritten signature in black ink that reads "Joshua Z. Schwartz MD". The signature is written in a cursive, flowing style.

Joshua Z. Schwartz, M.D., M.B.A.
Disease Area Head US Medical – Cardiovascular
Bristol-Myers Squibb Company